Sunday 06 May 11:30
Genetics, metabolomics and cardiovascular risk factors
-
Lale Tokgozoglu, Turkey
Lale Tokgozoglu
Ankara, Turkey
S. Lale Tokgözoğlu, M.D., F.A.C.C., F.E.S.C. was born in 1959 in Ankara, Turkey. She graduated from the Hacettepe University Faculty of Medicine in 1982 on the honor roll. After finishing the Internal Medicine Residency program in the Hacettepe University Faculty of Medicine Department of Internal Medicine on 1988, she completed a fellowship program on Cardiology and Atherosclerosis at the Baylor College of Medicine in Houston, Texas. Dr. Tokgözoğlu returned to the Hacettepe University in 1991 to become Associate Professor of Cardiology, and later Professor of Cardiology in 1998.
Prof. Tokgözoğlu has served on the Executive Committee of the European Society of Atherosclerosis as member between 2003 and 2005 ,as Secretary between 2005-2009 and as Vice President of the European Atherosclerosis Society between 2009-2013. She is currently President-elect of the European Atherosclerosis Society. She was the President of the 77th European Atherosclerosis Society meeting in İstanbul.
She also served as the President of the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. She has served for 2 years on board of the European Society of Cardiology Fellowship and Training Committee and for 2 years on the board of the Education Committee. She has also served first as Member-at-Large (Europe) of the Executive Committee of the International Society of Atherosclerosis, then as President of the European Federation of the International Atherosclerosis Society followed by the post of Secretary of the International Society of Atherosclerosis. She is still serving on their executive committee.
Prof. Tokgözoğlu has served on the Board of the Prevention Association of the European Society of Cardiology since 2011. She will be the chair of the Europrevent Congress in 2016 in İstanbul. Prof Tokgözoğlu has founded and chaired the Istanbul Consortium Chapter of the American College of Cardiology in 2010 which is a consortium of 16 countries. She was elected to be the European representative of the American College of Cardiology Assembly of International Governors Steering Committee in 2015.
She has been serving on the Scientific Program Committee of European Society of Cardiology since 1995. She has been a member of the young investigator award committees of the International Atherosclerosis Society in Stockholm 2000, European Atherosclerosis Society in Prague in 2005 and European Society of Cardiology in 2009, 2010 and 2015. Prof. Tokgözoğlu is currently a Fellow of the American College of Cardiology and European Society of Cardiology.
Prof. Tokgözoğlu has been elected to the ‘Science Academy in Turkey’ in 2014. Prof. Tokgözoğlu has served as the Secretary of the Lipid Working Group of the Turkish Society of Cardiology between 1994 and 1996, as President of the Lipid Working Group of the Turkish Society of Cardiology between 1998 and 2000. She has been on the Executive Committee of the Turkish Society of Cardiology for 6 years between 2000 and 2006 and as Vice President between 2008 and 2010 and is currently the President of the Turkish Society of Cardiology.
She has chaired the ‘Research Committee of the Turkish Society of Cardiology’ for 4 years. She is the founding member of the Atherosclerosis Research and Education Society in Turkey. Prof Tokgözoğlu is one of the authors of the ‘National Heart Health Policy’ for Turkey.
Prof Tokgözoğlu initiated the academic collaboration between Cornell-Weill Medical College and Hacettepe Universities in 2013 and is the Coordinator for the Cornell-Weill Medical College affairs in Hacettepe University.
Prof Tokgözoğlu has more than 200 publications, has authored 3 books and several book chapters. Prof. Tokgözoğlu is on the Editorial Board for European Heart Journal, Atherosclerosis, Anatolian Journal of Cardiology and Archives of the Turkish Society of Cardiology. She has won the “Prof. Dr. Şeref Zileli “Resident of the Year” Award in 1987; the Sandoz Scientific Award in 1989 and the “Young Investigator Award” of the Turkish Society of Cardiology in 1994 and second runner up in the Pfizer Cardiology Scientific Award in 1999.
Prof Tokgözoğlu works and publishes on atherosclerotic vascular disease, clinical lipidology, imaging ,hypertension and pulmonary hypertension.
- Yuji Matsuzawa, Japan
Mining the blood for new cardiometabolic markers
Robert Gerszten
Boston, USA
Robert E. Gerszten, MD is Chief of Cardiology at Beth Israel Deaconess Medical Center, the Herman Dana Professor of Medicine at Harvard Medical School, and a Senior Associate Member of the Broad Institute. Dr. Gerszten’s investigations focus on the nexus of cardiac and metabolic diseases. His translational research program leverages metabolomics and proteomic technologies for the discovery of new biomarkers and pathways contributing to atherogenesis and its complications. His highly interactive program collaborates across a spectrum of institutions, from the Broad Institute to the Framingham Heart Study, the Jackson Heart Study, the Diabetes Prevention Program, and the TIMI Study Group.
Genes can protect you from CVD – beyond classical risk factors
Heribert Schunkert, Munich, Germany
Heribert Schunkert
Munich, Germany
Heribert Schunkert, MD is Professor of Cardiology of the Technische Universitaet Munich, Director of the Cardiology Department, German Heart Centre Munich. He completed a research fellowship at Brigham and Women’s Hospital, Boston, USA and clinical fellowships at Beth Israel Hospital and at the Universitaetsklinikum, Regensburg and the Massachusetts General Hospital, Boston, USA. From 2002-2012 Prof. Schunkert was Director of Internal Medicine and Cardiology at the University of Luebeck. He conducts research in the molecular genetics of multifactorial cardiovascular disease, coordinates several EU- and BMBF-sponsored projects as well as the European-American Leducq network CADgenomics to identify the genetic roots of myocardial infarction. He is the author of more than 600 publications in international journals.
High-resolution lipoprotein phenotypes and cardiovascular outcomes
Samia Mora
Boston, USA
Samia Mora, MD, MHS is Associate Professor of Medicine, Harvard Medical School, Boston, Massachusetts, and Director of the Center for Lipid Metabolomics, Brigham and Women’s Hospital. Dr. Mora received her undergraduate and medical degrees from Harvard University, and completed her cardiology training at Massachusetts General Hospital and Johns Hopkins Hospital. A fellow of the American Heart Association and the American College of Cardiology, Dr. Mora has clinical and research interests in cardiovascular prevention. She serves on the Editorial Board of JAMA Internal Medicine. She has authored many peer-reviewed publications in connection with her research on risk factors and prevention of cardiovascular disease.
Genes can hurt you to develop CVD-beyond classical risk factors
Stefano Romeo, Gothenburg, Sweden
Monday 07 May 11:30
Can we really prevent atherosclerosis?
-
Lale Tokgozoglu, Turkey
Lale Tokgozoglu
Ankara, Turkey
S. Lale Tokgözoğlu, M.D., F.A.C.C., F.E.S.C. was born in 1959 in Ankara, Turkey. She graduated from the Hacettepe University Faculty of Medicine in 1982 on the honor roll. After finishing the Internal Medicine Residency program in the Hacettepe University Faculty of Medicine Department of Internal Medicine on 1988, she completed a fellowship program on Cardiology and Atherosclerosis at the Baylor College of Medicine in Houston, Texas. Dr. Tokgözoğlu returned to the Hacettepe University in 1991 to become Associate Professor of Cardiology, and later Professor of Cardiology in 1998.
Prof. Tokgözoğlu has served on the Executive Committee of the European Society of Atherosclerosis as member between 2003 and 2005 ,as Secretary between 2005-2009 and as Vice President of the European Atherosclerosis Society between 2009-2013. She is currently President-elect of the European Atherosclerosis Society. She was the President of the 77th European Atherosclerosis Society meeting in İstanbul.
She also served as the President of the ‘Atherosclerosis and Vascular Biology Working Group of the European Society of Cardiology’ between 2008 and 2010. She has served for 2 years on board of the European Society of Cardiology Fellowship and Training Committee and for 2 years on the board of the Education Committee. She has also served first as Member-at-Large (Europe) of the Executive Committee of the International Society of Atherosclerosis, then as President of the European Federation of the International Atherosclerosis Society followed by the post of Secretary of the International Society of Atherosclerosis. She is still serving on their executive committee.
Prof. Tokgözoğlu has served on the Board of the Prevention Association of the European Society of Cardiology since 2011. She will be the chair of the Europrevent Congress in 2016 in İstanbul. Prof Tokgözoğlu has founded and chaired the Istanbul Consortium Chapter of the American College of Cardiology in 2010 which is a consortium of 16 countries. She was elected to be the European representative of the American College of Cardiology Assembly of International Governors Steering Committee in 2015.
She has been serving on the Scientific Program Committee of European Society of Cardiology since 1995. She has been a member of the young investigator award committees of the International Atherosclerosis Society in Stockholm 2000, European Atherosclerosis Society in Prague in 2005 and European Society of Cardiology in 2009, 2010 and 2015. Prof. Tokgözoğlu is currently a Fellow of the American College of Cardiology and European Society of Cardiology.
Prof. Tokgözoğlu has been elected to the ‘Science Academy in Turkey’ in 2014. Prof. Tokgözoğlu has served as the Secretary of the Lipid Working Group of the Turkish Society of Cardiology between 1994 and 1996, as President of the Lipid Working Group of the Turkish Society of Cardiology between 1998 and 2000. She has been on the Executive Committee of the Turkish Society of Cardiology for 6 years between 2000 and 2006 and as Vice President between 2008 and 2010 and is currently the President of the Turkish Society of Cardiology.
She has chaired the ‘Research Committee of the Turkish Society of Cardiology’ for 4 years. She is the founding member of the Atherosclerosis Research and Education Society in Turkey. Prof Tokgözoğlu is one of the authors of the ‘National Heart Health Policy’ for Turkey.
Prof Tokgözoğlu initiated the academic collaboration between Cornell-Weill Medical College and Hacettepe Universities in 2013 and is the Coordinator for the Cornell-Weill Medical College affairs in Hacettepe University.
Prof Tokgözoğlu has more than 200 publications, has authored 3 books and several book chapters. Prof. Tokgözoğlu is on the Editorial Board for European Heart Journal, Atherosclerosis, Anatolian Journal of Cardiology and Archives of the Turkish Society of Cardiology. She has won the “Prof. Dr. Şeref Zileli “Resident of the Year” Award in 1987; the Sandoz Scientific Award in 1989 and the “Young Investigator Award” of the Turkish Society of Cardiology in 1994 and second runner up in the Pfizer Cardiology Scientific Award in 1999.
Prof Tokgözoğlu works and publishes on atherosclerotic vascular disease, clinical lipidology, imaging ,hypertension and pulmonary hypertension.
-
Jeroen J. Bax, The Netherlands
Jeroen J. Bax
Leiden, The Netherlands
Jeroen J. Bax is professor of Cardiology and Director of non-invasive cardiac imaging, at the department of Cardiology, Leiden University Medical Center, The Netherlands.
He has been working intensively with the European Society of Cardiology (ESC), and is currently serving as President of the ESC.
He has been Associate Editor of the American College Cardiology, and is currently Associate Editor of the European Heart Journal.
He has co-authored numerous scientific articles, has guided many PhD fellows and his main interests of research include imaging in heart failure, stable coronary artery disease, valvular heart disease and atrial fibrillation.
Will aggressively lowering of LDL prevent atherosclerosis?
Alberico L. Catapano, Milan, Italy
Alberico L. Catapano
Milan, Italy
Alberico L. Catapano was born in Milan in 1952. He received his degree from the University of Milan in 1975 and specialization in clinical pharmacology in 1979. Since 1972, Professor Catapano has been involved in the fields of atherosclerosis, lipids, lipoproteins and genetic dyslipidaemias, and has made landmark observations regarding heat shock proteins and pentraxins in atherogenesis, on high-density lipoprotein in the modulation of the immune response, and on the identification of possible therapeutic targets by exploiting genetic information. Alberico Catapano is Full Professor of Pharmacology at the University of Milan, Director of the Laboratory of Lipoproteins, Immunity and Atherosclerosis of the Center for the Study of Atherosclerosis at the “Bassini” Hospital. He is also the Director of the Center of Epidemiology and Preventive Pharmacology of the University of Milan. He is the immediate past President of the European Atherosclerosis Society (EAS) and Chairman of the EAS/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinaemias. He holds board positions on several learned scientific societies, including the Italian Society for the Study of Atherosclerosis. He is also President of the Italian Society of Clinical and Experimental Therapy (SITeCS) and General Director of the SISA Foundation (Italian Society for the Study of Atherosclerosis).
Professor Catapano has authored more than 390 scientific papers in peer-reviewed journals and several books in the area of the atherosclerosis, lipoproteins and lipid metabolism. He is Editor of Atherosclerosis Supplements and also Co-editor of Atherosclerosis and Associate Editor of other scientific journals. According to Google Scholar, his H-index is 67 and the last 5 years has received more than 15,000 citations.
Early therapy versus late intervention; what works?
Diedrick Grobbee, Utrecht, The Netherlands
Diedrick Grobbee
Utrecht, The Netherlands
Diederick Grobbee is Professor of Clinical Epidemiology, Founder of the Julius Center, University Medical Center Utrecht. He is CSO of Julius Clinical, full service Academic CRO, Previously Professor of Clinical Epidemiology Erasmus University and Associate Professor Harvard University. Professor Grobbee has Honorary appointments in Sydney and Kuala Lumpur. He is listed in the top 100 global most influential biomedical researchers (Eur J Clin Invest 2013), Senior-consulting-editor European Journal of Preventive Cardiology (previously editor-in-chief), President European Association of Preventive Cardiology, Distinguished University Professor of International Health Sciences and Global Health (Utrecht University).
He is Fellow of the Royal Dutch Academy of Sciences and was Knighted by the Dutch King (2017). Professor Grobbee has published more than 1330 scientific papers and has an H-index (WoS) of 138.
Will inhibiting thrombus formation prevent acute coronary syndromes?
Stephan Gielen, Halle, Germany
Stephan Gielen
Halle, Germany
As President of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR) 2012-14, as National CVD Prevention Coordinator for Germany, and as Secretary of the Project Group on Prevention of the German Cardiac Society Stephan Gielen has been active in cardiovascular prevention. He works as Director of the Dept. of Cardiology, Angiology, and Intensive Care Medicine at the Klinikum Lippe, Detmold, Germany and is member of the Medical Faculty of the Martin-Luther-University Halle-Wittenberg, Germany. He is editor of the ESC Textbook of Preventive Cardiology, co-author of the ESC Textbook of Cardiovascular Medicine and author/coauthor of more than 150 peer-reviewed scientific articles.
Reality check: Can we get to goals in guidelines?
Ulrich Laufs, Homburg, Germany
Ulrich Laufs
Homburg, Germany
In July 2017, UL was appointed as the Professor of Cardiology at Leipzig University and as chairman of cardiology at Leipzig University Hospital.
Ulrich Laufs was born in Göttingen, Germany, and studied philosophy and medicine in Bochum. He completed his training at the University of Hamburg, where he did his medical thesis at the Institute of Pharmacology. After his residency at the University of Köln he worked for 2 years at the Cardiovascular Division of the Brigham and Women´s Hospital in Boston. In the lab of Jim Liao he described the cholesterol-independent regulation of endothelial nitric oxide synthase by statins, a mechanism that contributes to the effects of statins on ischemic stroke. Under the mentorship of Michael Böhm he undertook his fellowships at the University of Köln and the University of Saarland.
Before his recent move to Leipzig, Ulrich Laufs was Professor for Clinical and Experimental Medicine and served as Vice Chairman of the Department of Internal Medicine, Cardiology, Angiology and Intensive Medicine at the University of Saarland, Homburg, Germany. He has received numerous honours including a first place of the Young Investigator Award of the American College of Cardiology, the Population Sciences Award of the European Society of Cardiology, the Paul-Martini-Award, and the Albert-Fraenkel-Award of the German Cardiac Society. UL serves in serveral editorial boards and as a member of the federal drug commissions of the German Physicians (Arzneimittelkommission der Deutschen Ärzteschaft, AkdÄ) and the German Pharmacists (Arzneimittelkommission der Deutschen Apotheker, AMK). He is chairman / member of the nucleus of the working groups on “heart failure”, “heart and brain” and on “prevention” of the German Society of Cardiology.
Professor Laufs works as interventional cardiologist. He has a special clinical interest in lipid disorders and heads a research group with special focus on the cellular and molecular mechanisms and clinical studies of cardiovascular prevention. UL enjoys the combination of acute and interventional patient care with cardiovascular prevention and translational research. His current research is focused on
- Vascular biology, ischemic stroke and cardiovascular prevention. His group has a special interest in the study of the molecular effects of physical exercise, such as the molecular regulation of cellular senescence.
- Clinical and experimental research in lipid metabolism. The group has characterized several cholesterol-independent effects of statins mediated by isoprenylation of small G proteins. Currently his group is interested in the cellular actions of triglycerides, plant sterols, PCSK9 and ApoCIII.
- Pathophysiology of myocardial remodelling and fibrosis. UL headed a research consortium funded by the Deutsche Forschungsgemeinschaft (DFG) that elucidates the signalling during adaptive and maladaptive myocardial remodelling, a topic that is closely related to his projects addressing small G protein function and physical exercise.
- Cardiovascular pharmacotherapy. The clinical trial unit of his research group conducts investigator initiated studies with a special interest in topics related to medication adherence and participates in many multi-center trials.
